Yissum Introduces a Novel Technology for Manufacturing an Anti-Malaria Drug in Tobacco
Complete the form below to unlock access to ALL audio articles.
Combating malaria is one of the eight Millennium Development Goals described in the United Nations Millennium Declaration signed by all UN members at the year 2000.
A key intervention to control malaria is prompt and effective treatment with artemisinin-based combination therapies.
Artemisinin is a natural compound from Artemisia annua (sweet wormwood) plants, but low-cost artemisinin-based drugs are lacking because of the high cost of obtaining the natural or chemically synthesized drug.
Despite extensive efforts invested in the last decade in metabolic engineering of the drug in both microbial and heterologous plant systems, production of artemisinin itself was never achieved.
Now, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University of Jerusalem, introduces a novel method allowing artemisinin production in a heterologous (that is, other than A. annua) plant system, such as tobacco.
The method was developed by Professor Alexander Vainstein from the Robert H. Smith Faculty of Agriculture, Food and Environment at the Hebrew University, and sponsored by a fellowship of Mr. Isaac Kaye.
It was published under the title Generation of the Potent Anti-Malarial Drug Artemisinin in Tobacco in the latest issue of the prestigious publication Nature Biotechnology.
Professor Vainstein and his graduate student Mr. Moran Farhi have developed genetically engineered tobacco plants carrying genes encoding the entire biochemical pathway necessary for producing artemisinin.
In light of tobacco’s high biomass and rapid growth, this invention will enable a cheap production of large quantities of the drug, paving the way for the development of a sustainable plant-based platform for the commercial production of an anti-malarial drug.
The invention is patented by Yissum, which is now seeking a partner for its further development.
Yaacov Michlin, CEO of Yissum said, "Professor Vainstein's technology provides, for the first time, the opportunity for manufacturing affordable artemisinin by using tobacco plants. We hope that this invention will eventually help control this prevalent disease, for the benefit of many millions of people around the globe, and in particular in the developing world."
